MRK•benzinga•
Merck Secures Canadian Regulatory Nod For KEYTRUDA In Skin Cancer After Resection
Summary
Health Canada has granted approval for Merck’s (NYSE: MRK) KEYTRUDA (pembrolizumab) for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 13, 2022 by benzinga